Filing Flows › Nektar Therapeutics (NKTR) › Q1 2026 › vs Q4 2025
Nektar Therapeutics (NKTR) Q1 2026 vs Q4 2025 (quarter over quarter)
Nektar Therapeutics's revenue fell $10.9M (-50%) from $21.8M in Q4 2025 to $10.9M in Q1 2026.
Nektar Therapeutics, Q1 2026: revenue $10.9M (+4% year over year), operating margin -359.6%, net loss $44.9M, operating cash flow −$44.3M. The chart draws each line against Q4 2025, the increases inside each band.
Every line
| Line | Q1 2026 | Q4 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $10.9M | $21.8M | −$10.9M | -50% |
| Net loss | $44.9M | $36.1M | $8.8M | +24% |
| Costs & expenses | $55.8M | $57.9M | −$2.1M | -4% |
| Operating costs | $49.9M | $49.5M | $443K | +0.9% |
| Interest & other, net | $5.8M | $8.4M | −$2.6M | -31% |
| Income tax | $64K | $31K | $33K | +106% |
| Research & development | $35.7M | $29.7M | $6.0M | +20% |
| General & admin | $13.4M | $11.2M | $2.3M | +20% |
| Other operating costs | $796K | $8.6M | −$7.8M | -91% |
| Operating cash sources | $47.8M | $67.3M | −$19.5M | -29% |
| Depreciation & amortization | $151K | $190K | −$39K | -21% |
| Share-based compensation | $3.4M | $2.2M | $1.2M | +53% |
| Cash used in operations | $44.3M | $65.0M | −$20.7M | -32% |
| Net loss absorbed | $44.9M | $36.1M | $8.8M | +24% |
| Working capital & other | $2.9M | $31.3M | −$28.4M | -91% |
Questions
How much did Nektar Therapeutics's revenue grow quarter over quarter in Q1 2026?
Nektar Therapeutics's revenue fell $10.9M (-50%) from $21.8M in Q4 2025 to $10.9M in Q1 2026.